Cumberland Pharmaceuticals Inc Revenue Growth Rates (CPIX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cumberland Pharmaceuticals Inc   (NASDAQ: CPIX)
 

CPIX's Revenue Growth by Quarter and Year

Cumberland Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CPIX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.17
1st Quarter March 9.13
FY 9.30

CPIXs Annual Revenue
Cumberland Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 44.52 millions
Cumberland Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 37.87 millions
Cumberland Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 39.55 millions
Cumberland Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 42.01 millions
Cumberland Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 35.99 millions




CPIX Revenue second quarter 2025 Y/Y Growth Comment
Cumberland Pharmaceuticals Inc reported drop in Revenue in the second quarter 2025 by -98.46% to $ 0.17 millions, from the same quarter in 2024.
This represents worst decline in recent Company history.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 201 other companies have achieved higher Revenue growth. While Cumberland Pharmaceuticals Inc ' s Revenue meltdown of -98.46% ranks overall at the positon no. 3919 in the second quarter 2025.


CPIX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 31.03 % 11.66 % 2.52 %
3rd Quarter September - -8.8 % -9.91 % -11.57 %
2nd Quarter June -98.46 % 10.05 % -9.55 % 5.73 %
1st Quarter March -22.03 % 37.76 % -7.81 % -17.53 %
FY   - 17.53 % -4.22 % -

Financial Statements
Cumberland Pharmaceuticals Inc 's second quarter 2025 Revenue $ 0.17 millions CPIX's Income Statement
Cumberland Pharmaceuticals Inc 's second quarter 2024 Revenue $ 10.84 millions Quarterly CPIX's Income Statement


CPIX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 65.02 % 14.85 % -7.33 %
3rd Quarter September - -23.52 % -7.72 % -7.35 %
2nd Quarter June -98.18 % -7.43 % 15.88 % 18.11 %
1st Quarter March -33.26 % 12.16 % -9.09 % 1.1 %
FY (Year on Year)   - 17.53 % -4.22 % -


Back to CPIX Growth rate Comparisons >> Back to CPIX Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #202
Healthcare Sector #575
Overall #3919

Revenue Y/Y Growth Statistics
High Average Low
49.02 % -0.1 % -98.46 %
(Mar 31 2015)   (Mar 31 2014)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #202
Healthcare Sector #575
Overall #3919
Revenue Y/Y Growth Statistics
High Average Low
49.02 % -0.1 % -98.46 %
(Mar 31 2015)   (Mar 31 2014)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Cumberland Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
64.95 % -0.21 % -98.18 %
(Dec 31 2025)  


CPIX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Cumberland Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -98.18% to $ 0.17 millions, from $ 9.13 millions achived in the previous reporting period.

But that's not important problem, as Cumberland Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 212 other companies have achieved higher Revenue quarter on quarter growth. While Cumberland Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3885.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #213
Healthcare Sector #589
Overall #3885
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #213
Healthcare Sector #589
Overall #3885
Revenue Q/Q Growth Statistics
High Average Low
64.95 % -0.21 % -98.18 %
(Dec 31 2025)  


CPIX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Cumberland Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -98.18% to $ 0.17 millions, from $ 9.13 millions achived in the previous reporting period.

But that's not important problem, as Cumberland Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 212 other companies have achieved higher Revenue quarter on quarter growth. While Cumberland Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3885.


Cumberland Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 31.27 $ 41.94 $ 44.52 $ 41.28 $ 42.07
Y / Y Revenue Growth (TTM) -25.68 % 2.08 % 17.57 % 12.21 % 11.34 %
Year on Year Revenue Growth Overall Ranking # 1351 # 1661 # 2261 # 2509 # 1850
Seqeuential Revenue Change (TTM) -25.44 % -5.8 % 7.86 % -1.89 % 2.41 %
Seq. Revenue Growth (TTM) Overall Ranking # 2363 # 1388 # 1711 # 2290 # 1656


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Cumberland Pharmaceuticals Inc reported a drop in Revenue by -25.68% year on year, to $31 millions, compare to the 2.08% growth at Mar 31 2026.

In the Healthcare sector 234 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1351, from total ranking in previous quarter at 1661.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 109
Healthcare Sector # 235
Overall # 1351

Revenue TTM Y/Y Growth Statistics
High Average Low
25.56 %
 -0.66 %
-38.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 109
Sector # 340
S&P 500 # 2363
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Cumberland Pharmaceuticals Inc reported a drop in Revenue by -25.68% year on year, to $31 millions, compare to the 2.08% growth at Mar 31 2026.

In the Healthcare sector 234 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1351, from total ranking in previous quarter at 1661.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 109
Healthcare Sector # 235
Overall # 1351

Revenue TTM Y/Y Growth Statistics
High Average Low
25.56 %
-0.66 %
-38.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 109
Sector # 340
S&P 500 # 2363




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CPIX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Cumberland Pharmaceuticals Inc Revenue Growth Rates (CPIX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cumberland Pharmaceuticals Inc (CIK 1087294).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001087294-26-000062
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cumberland Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.